JNJ - Johnson & Johnson Stock Analysis
Johnson & Johnson (JNJ) is a publicly traded company listed on the . It operates in the industry, part of the broader sector. The company has a market capitalization of 594.63B, generates annual revenue of 97.93B, and reports net income of 21.04B. As of the latest data, the stock is trading at 247.02 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is moderately valued and aligns with market expectations for established companies. The PEG ratio is within a normal range, suggesting the stock is fairly priced for its expected growth. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. The stock offers a moderate dividend yield (2.16%), which may appeal to income-focused investors. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at No Data (None), indicating current market sentiment. Institutional ownership is reported at 77.30%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 59.19%, trading within a 52-week range of 154.80 - 269.43.
JNJ - Johnson & Johnson
247.02
Analyst Consensus
No Data None
JNJ – Analyst Rating Summary
No analyst data available
No Data
| Index: | DJIA, S&P 500 | P/E: | 28.63 | EPS (ttm): | 8.63 | Insider Own: | 0.14% | Shs Outstand: | 2.41B | Perf Week: | -6.22% |
| Market Cap: | 594.63B | Forward P/E: | 19.22 | EPS next Y: | 12.85 | Insider Trans: | -9.41% | Shs Float: | 2.40B | Perf Month: | 2.55% |
| Income(ttm): | 21.04B | PEG: | 1.96 | EPS next Q: | 3.03 | Inst Own: | 77.30% | Short Float: | 1.11% | Perf Quarter: | 2.88% |
| Revenue(ttm): | 97.93B | P/S: | 6.07 | EPS this Y: | 7.73% | Inst Trans: | 0.28% | Short Ratio: | 3.27 | Perf Half Y: | 17.79% |
| Book/sh: | 33.73 | P/B: | 7.32 | EPS next Y: | 10.58% | ROA: | 10.66% | Short Interest: | 26.58M | Perf Year: | 59.19% |
| Cash/sh: | 9.16 | P/C: | 26.97 | EPS next 5Y: | 9.78% | ROE: | 26.42% | 52W Range: | 154.80 - 269.43 | Perf YTD: | 19.36% |
| Dividend Est.: | 5.34 (2.16%) | P/FCF: | 33.44 | EPS past 3/5Y: | 17.88% 14.90% | ROIC: | 17.72% | 52W High: | 269.43 -8.32% | Beta: | 0.23 |
| Dividend TTM: | 5.24 (2.12%) | Quick Ratio: | 0.77 | Sales past 3/5Y: | 5.56% 2.67% | Gross Margin: | 75.08% | 52W Low: | 154.80 59.57% | Perf 5Y: | 46.71% |
| Dividend Ex-Date: | May 26, 2026 | Current Ratio: | 1.03 | EPS Y/Y TTM: | -3.56% | Oper. Margin: | 26.79% | RSI (14): | 48.75 | Volatility: | 2.34% 2.33% |
| Employees: | 140800 | Debt/Eq: | 0.68 | Sales Y/Y TTM: | 8.06% | Profit Margin: | 21.48% | Recom: | 1.88 | Target Price: | 271.43 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.46 | EPS Q/Q: | -0.92% | Payout: | 46.59% | Rel Volume: | 1.30 | Prev Close: | 253.85 |
| Sales Surprise: | 1.15% | EPS Surprise: | 1.59% | Sales Q/Q: | 6.61% | Earnings: | Jul 15 BMO | Avg Volume: | 8.12M | Price: | 247.02 |
| SMA20: | -1.25% | SMA50: | 3.97% | SMA200: | 11.16% | Undervalued: 9.88% | Volume: | 10,547,314 | Change: | -2.69% | |
Graham Classic formula value: 217.45
(P/E=8 * 1g) Min value: 137.78
(current P/E * 2g) Max value: 373.44
Average value: 242.89
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.